VEINCENTRE acquired by CBPE CAPITAL
Context
CBPE Capital has completed a majority investment in Veincentre, acquiring the stake previously held by Palatine Private Equity alongside the company,s founders. This transaction marks a secondary LBO for the specialist clinic group, which saw significant growth under Palatine,s three-year ownership, including the expansion from 7 to 22 clinics. The deal was structured to support the current management team, led by CEO Maurice McLoughlin, in the next phase of their national expansion strategy. The rationale for the acquisition is rooted in the high demand for specialized outpatient vascular services in the UK and Veincentre,s proven, scalable clinical model. CBPE intends to leverage its extensive experience in multi-site healthcare to further increase the group's clinic density across the UK. The operation was supported by a debt advisory from FRP Advisory and commercial due diligence from Candesic.
VEINCENTRE, which reported an EBITDA margin of LOGIN in 2022, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Veincentre is the United Kingdom,s leading specialist provider of minimally invasive treatments for venous insufficiency, primarily focusing on the treatment of varicose veins and venous ulcers. The company operates a high-efficiency business model centered on outpatient procedures performed under local anesthetic, allowing patients to undergo complex vascular treatments with rapid recovery times. Its value proposition is built on clinical excellence, utilizing a dedicated team of consultant vascular surgeons and interventional radiologists to provide specialized care across a growing national network of clinics. Veincentre,s strategy focuses on increasing patient access to high-quality vascular services that are often underserved by traditional healthcare systems. By concentrating exclusively on venous reflux disorders, the group achieves significant operational expertise and high patient satisfaction ratings. The company serves a large addressable market, as venous conditions affect millions of people in the UK, and it continues to expand its geographic footprint to maintain its position as the premier dedicated venous clinical group in the country.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (GBP)
Similar deals in Healthcare & Pharma
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 06/2023 | PARQUEST CAPITAL | IMANEO | FRANCE | Health Providers | Parquest acquired a majority stake in the newly formed Imaneo group from its 70 associate radiologists. The transaction was the result of a competitive process involving both French and international private equity funds, as well as corporate interest from the life sciences sector. This strategic operation facilitates the merger of three independent radiology practices into a single unified platform. The associate radiologists, who were already shareholders in their respective legacy firms, reinvested significantly to retain nearly 50% of the new group's capital |
| 11/2022 | RADNET | HEART & LUNG IMAGING | UNITED KINGDOM | Health Providers | RadNet, a US-based medical imaging specialist, has acquired a 75% majority stake in Heart & Lung Imaging Limited (HLH), a UK-based teleradiology network focused on detecting and diagnosing lung and cardiovascular diseases. This move is part of RadNet's strategy to enhance its capabilities in early cancer detection and develop solutions that combine artificial intelligence (AI) with specialized medical expertise. Through this acquisition, RadNet expands its presence in the UK and positions itself in a market with significant growth prospects, driven in part by the National Health Service's (NHS) Targeted Lung Health Check (TLHC) program |
| 09/2022 | ORADIANSE | REVEL | FRANCE | Health Providers | Oradianse, a leading group of radiologists, has acquired a radiology practice in Revel, located in the Haute-Garonne region near Toulouse. This move is part of the company's territorial development strategy, aimed at strengthening its presence in the Occitanie region and consolidating its national network of medical imaging centers. The practice, previously owned by Dr. Gazel since 2019, was seeking a successor to ensure continuity of care for patients in the area as Dr. Gazel prepares for retirement |
| 09/2022 | EURAZEO | IMAPOLE | FRANCE | Health Providers | Eurazeo has partnered with Bpifrance to complete a major investment of over EUR 50 million in Imapole. This investment marks a strategic turning point in the professionalization of regional medical imaging groups in France. The strategic rationale for this transaction centers on a "platform-build" play, merging the group’s practitioner-led operational depth with the sponsors' extensive expertise in healthcare scaling and digital transformation. This structural alignment provides the organization with the institutional capital and strategic hardware required to address the high demand for imaging capacity in under-served areas |
| 08/2022 | FREEMAN SPOGLI | EVERVET PARTNERS | UNITED STATES | Health Providers | Freeman Spogli & Co. made a significant investment in EverVet Partners, partnering alongside existing investor Tailwind Capital while EverVet's founders and management retained meaningful equity stakes. The transaction provided growth capital to accelerate EverVet's expansion in the consolidating U.S. veterinary services market. The deal made strategic sense because EverVet's veterinarian-led platform model aligned perfectly with Freeman Spogli's consumer services expertise, while Tailwind's foundational support transitioned into continued partnership |
| 07/2022 | INFRAVIA CAPITAL | UNIVET | FRANCE | Health Providers | InfraVia Capital Partners acquired a minority stake in Univet from Platina Equity Solutions, which had been a partner since 2018. The transaction was structured as a combination of secondary share purchases and a primary capital increase, financed entirely through equity from InfraVia's EUR5 billion European Fund V. The founding management and associated veterinarians retained the majority of the capital. The investment is intended to accelerate Univet's buy-and-build strategy, supporting its ambition to reach EUR100 million in revenue by the end of 2022 |
| 07/2022 | ANDERA PARTNERS | GROUPE RESONANCE IMAGERIE | FRANCE | Health Providers | R�sonance Imagerie, a prominent French medical imaging group, has secured a major financing package from Andera MidCap, Ardian Private Debt, and Five Arrows Debt Partners. Established in 2011, the group currently operates a network of 15 centers across Paris, �le-de-France, and the Centre-Val-de-Loire region, managing 23 high-tech units including MRIs and scanners. |
| 07/2022 | LATOUR CAPITAL | PHARMACIE LAFAYETTE - GROUPE HYGIE31 | FRANCE | Health Providers | Latour Capital and Bpifrance acquired a majority stake in Hygie31, the holding company of Pharmacie Lafayette, from Five Arrows (Rothschild & Co). The deal aims to accelerate the group's development in France and Europe through organic growth and an ambitious buy-and-build strategy. |
| 06/2022 | ARDIAN | SIMAGO | FRANCE | Health Providers | Ardian acquired a significant minority stake in Simago. The investment was designed to support the group's rapid "buy-and-build" strategy in a highly fragmented French market. Unlike traditional LBOs, the deal was structured to preserve the medical independence of the associate radiologists, who continue to hold the majority of the capital and voting rights alongside the founding management team. |
| 06/2022 | TRITON PARTNERS | ESPERI CARE | FINLAND | Health Providers | Triton Partners, via its Triton Smaller Mid Cap Fund II, acquired a majority stake in Esperi Care Oy from a consortium of its former creditors, including Danske Bank, SEB, and Ilmarinen, which remain as minority shareholders. The transaction implies a majority control transfer while preserving continuity of public‑sector and employee‑management relationships, with Triton committing to a substantial capital investment to support further service development and operational improvements. The strategic rationale is rooted in Esperi Care’s established position, business model built on recurring and contract‑based care fees, strong regulatory and societal mandate |
REFERENCES
EBITDA range: 5M - 25M GBP
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of VEINCENTRE by CBPE CAPITAL are reserved for mynth community members. Register for free to unlock full data.
Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).
Press release: view release
Target: veincentre
Acquirer: cbpe capital